Innate Pharma (IPHA) Common Equity (2017 - 2019)

Innate Pharma (IPHA) has 3 years of Common Equity data on file, last reported at $240.7 million in Q4 2019.

• For the quarter ending Q4 2019, Common Equity rose 26.07% year-over-year to $240.7 million; the trailing twelve-month figure through Dec 2019 stood at $240.7 million (up 26.07% YoY), and the FY2019 full-year result was $240.7 million, up 26.07% from the prior year.
• Common Equity for Q4 2019 stood at $240.7 million, up from $190.9 million in the prior quarter.
• Across five years, Common Equity topped out at $240.7 million in Q4 2019 and bottomed at $101.2 million in Q4 2017.
• The 3-year median for Common Equity is $190.9 million (2018), against an average of $177.6 million.
• The widest annual swing landed in 2018, when Common Equity surged 88.61%; it then advanced 26.07% in 2019.
• A 3-year view of Common Equity shows it stood at $101.2 million in 2017, then soared by 88.61% to $190.9 million in 2018, then increased by 26.07% to $240.7 million in 2019.
• The last three Common Equity figures came in at $240.7 million (Q4 2019), $190.9 million (Q4 2018), and $101.2 million (Q4 2017), per Business Quant data.

Peer Comparison